Full Press Release Details
FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
MIRM Positive Sentiment
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Key Takeaway: Mirum Pharmaceuticals and Incyte have received U.S. FDA approval for Atebrioz™ (zilurgisertib), a treatment for both adult and pediatric patients suffering from Fibrodysplasia Ossificans Progressiva (FOP). This approval marks a significant advancement in addressing the needs of patients with this rare condition. The collaboration highlights the commitment of both companies to develop innovative therapies.
Market Sentiment Analysis
POSITIVE FACTORS
- FDA approval signifies a major milestone for Mirum and Incyte.
- Atebrioz™ offers a new treatment option for patients with FOP.
- Approval supports the need for innovative therapies in rare diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+19%
120-day peak, hindsight
Typical move
2.8%
average across 14 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
Blinded CDCA
Phase 3 · CTX
Frequently Asked Questions
What is Atebrioz™ used for?
Atebrioz™ (zilurgisertib) is approved for treating Fibrodysplasia Ossificans Progressiva.
Who developed Atebrioz™?
Atebrioz™ was developed by Mirum Pharmaceuticals and Incyte.
What does FDA approval mean for Atebrioz™?
FDA approval allows Atebrioz™ to be marketed as a treatment for FOP patients.
Is Atebrioz™ for adults, children, or both?
Atebrioz™ is approved for both adult and pediatric patients.